Poly Medicure Ltd (POLYMED) is currently trading at 1,797.70 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Poly Medicure Limited is an India-headquartered medical devices manufacturer supplying infusion therapy, renal/dialysis, cardiology, orthopedics and other fluid-management products to over 125 countries, operating multiple manufacturing sites across India, China, Egypt and Italy and selling through a global distributor network and recently acquired European businesses. Q3 FY26 consolidated revenue rose 16.4% YoY to Rs.493.7 crore with gross margin expansion (~300 bps YoY) but reported PAT compression due to one-off labour-code provisioning and acquisition-related expenses; consolidated operating EBITDA margin remains within the 25–27% guidance band at 24.2% for the quarter and 25.8% for 9M. Strategic inorganic moves are material: Poly Medicure completed acquisitions of PendraCare and Citieffe in FY26, adding immediate revenue (~Rs.48–49 crore in Q3) and EU/FDA-approved products, while management is integrating operations and aiming to leverage India cost base to scale European technologies globally. Innovation momentum is significant: 19 new products launched in 9M FY26, ~100 R&D staff across India, Italy and the Netherlands, 394 patents reported, and DCGI approvals for high-ASP cardiology devices (IVL and DEB) that are expected to lift ASPs and open new value pools. Balance-sheet strength and capex plan: cash & equivalents ~Rs.840 crore at Dec 31, 2025 with Rs.234 crore capex in 9M FY26, land acquisition at YEIDA for a medical device park, and three planned plants coming online in 18–24 months to support growth and product upshift.

Over the past 52 weeks, Poly Medicure Ltd has traded between a low of ₹1,184.00 and a high of ₹2,143.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Poly Medicure Ltd has a market capitalization of approximately 17,519.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Poly Medicure Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 55.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 17,519.32 Cr, Poly Medicure Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Poly Medicure Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Poly Medicure Ltd is 55.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone revenue was INR 431 crore in Q1 FY27, up 12.3% year-on-year, with domestic growth of 16.2% and international growth of 10%.

Consolidated revenue from operations rose to ₹525.4 crore in Q1 FY27 from ₹403.2 crore in Q1 FY26, a 30.3% year-on-year increase.

Poly Medicure’s board approved the unaudited standalone and consolidated results on August 7, 2026, for the quarter ended June 30, 2026.

It is reportedly ₹86 crore, as stated in a source alert, and the figure is not independently verified against regulatory filings in the provided context.